CA3217579A1 - Method of treating alzheimer's disease - Google Patents
Method of treating alzheimer's disease Download PDFInfo
- Publication number
- CA3217579A1 CA3217579A1 CA3217579A CA3217579A CA3217579A1 CA 3217579 A1 CA3217579 A1 CA 3217579A1 CA 3217579 A CA3217579 A CA 3217579A CA 3217579 A CA3217579 A CA 3217579A CA 3217579 A1 CA3217579 A1 CA 3217579A1
- Authority
- CA
- Canada
- Prior art keywords
- treatment according
- subject
- administered
- daily dose
- hydrochloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Plant Substances (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163190299P | 2021-05-19 | 2021-05-19 | |
| US63/190,299 | 2021-05-19 | ||
| US202163192398P | 2021-05-24 | 2021-05-24 | |
| US63/192,398 | 2021-05-24 | ||
| US202263331011P | 2022-04-14 | 2022-04-14 | |
| US63/331,011 | 2022-04-14 | ||
| PCT/US2022/030020 WO2022246059A1 (en) | 2021-05-19 | 2022-05-19 | Method of treating alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3217579A1 true CA3217579A1 (en) | 2022-11-24 |
Family
ID=84104208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3217579A Pending CA3217579A1 (en) | 2021-05-19 | 2022-05-19 | Method of treating alzheimer's disease |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20220370443A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4340834A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024518455A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240021760A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022275939A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3217579A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023013537A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022246059A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6635652B1 (en) * | 1999-07-30 | 2003-10-21 | Zenyaku Kogyo Kabushiki Kaisha | Azaindolizinone derivatives and cerebral function improvers containing the same as the active ingredient |
| US20100168135A1 (en) * | 2008-12-15 | 2010-07-01 | Kim Nicholas Green | Method of Inducing Cleavage of Amyloid Precursor Protein to Form a Novel Fragment |
| CN102573839A (zh) * | 2009-05-11 | 2012-07-11 | 加利福尼亚大学董事会 | 降低泛素化蛋白水平的方法 |
| WO2012094615A2 (en) * | 2011-01-07 | 2012-07-12 | Zenyaku Kogyo Kabushikikaisha | Use of cav3.1 selective t-type calcium channel antagonists |
-
2022
- 2022-05-19 JP JP2023568654A patent/JP2024518455A/ja active Pending
- 2022-05-19 CA CA3217579A patent/CA3217579A1/en active Pending
- 2022-05-19 EP EP22805475.5A patent/EP4340834A4/en active Pending
- 2022-05-19 MX MX2023013537A patent/MX2023013537A/es unknown
- 2022-05-19 KR KR1020237039101A patent/KR20240021760A/ko active Pending
- 2022-05-19 AU AU2022275939A patent/AU2022275939A1/en active Pending
- 2022-05-19 WO PCT/US2022/030020 patent/WO2022246059A1/en not_active Ceased
- 2022-05-19 US US17/748,451 patent/US20220370443A1/en not_active Abandoned
-
2024
- 2024-01-23 US US18/420,250 patent/US20240156812A1/en not_active Abandoned
-
2025
- 2025-05-19 US US19/211,429 patent/US20250375444A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022246059A1 (en) | 2022-11-24 |
| US20240156812A1 (en) | 2024-05-16 |
| AU2022275939A1 (en) | 2023-11-16 |
| EP4340834A1 (en) | 2024-03-27 |
| KR20240021760A (ko) | 2024-02-19 |
| MX2023013537A (es) | 2024-02-06 |
| US20250375444A1 (en) | 2025-12-11 |
| US20220370443A1 (en) | 2022-11-24 |
| EP4340834A4 (en) | 2025-04-02 |
| JP2024518455A (ja) | 2024-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chapple et al. | A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial | |
| JP2025031741A (ja) | ムスカリン性受容体活性化によって改善される疾患の治療のための方法および組成物 | |
| EP0866691B1 (en) | Sublingual and buccal administration of selegiline | |
| US20110319384A1 (en) | Pharmaceutical Compositions | |
| JP2019526571A (ja) | 認知症の処置 | |
| JP2020510675A (ja) | ミトコンドリア起源のrosの産生の特異的阻害剤を使用した、薬物誘発qt間隔延長に関連するリスクの予防 | |
| US11826321B2 (en) | Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions | |
| US20220370454A1 (en) | Methods for treating central nervous system disorders with muscarinic receptor activation and antipsychotics | |
| CA2845039A1 (en) | Combinations of a 5-ht4 receptor agonist and a pde4 inhibitor for use in therapy | |
| KR20250084183A (ko) | 다발성 경화증에 대한 치료용 티로신 키나제 저해제 | |
| US20250375444A1 (en) | Method of treating alzheimer’s disease | |
| JP2022514659A (ja) | ドーパミン作動性cns障害の治療におけるly3154207の使用のための用量レジメン | |
| CN104623671A (zh) | 含有乙酰胆碱酯酶抑制剂和二甲双胍的复方药用组合物 | |
| HK40103192A (en) | Method of treating alzheimer's disease | |
| CN117529318A (zh) | 治疗阿尔茨海默病的方法 | |
| EP4069232B1 (en) | Masupirdine for treating behavioral and psychological symptoms in dementia | |
| US20240358693A1 (en) | Methods of treating pain | |
| WO2020014072A1 (en) | Neostigmine pharmaceutical combination for treating myasthenia gravis | |
| WO2019023175A1 (en) | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE AND NEOSTIGMINE AND AN ANTAGONIST NK-1 FOR THE TREATMENT OF SEVERE MYASTHENIA | |
| HK40071665A (en) | Treating behavioral and psychological symptoms in dementia patients | |
| CA3219499A1 (en) | Synergistic effects on weight loss, improved quality of life and gastro-intestinal side effects with a composition of orlistat and acarbose | |
| US20230364104A1 (en) | Pharmaceutical combination for the treatment of human hypocholinergic disorders | |
| EA045669B1 (ru) | Способы лечения поведенческих и психологических симптомов у пациентов с деменцией | |
| HK40071665B (en) | Treating behavioral and psychological symptoms in dementia patients | |
| CN117957003A (zh) | 治疗神经退行性疾病的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250508 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250508 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260512 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260512 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20260519 |
|
| D16 | Fast track examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D16-D106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ADVANCED EXAMINATION REQUESTED - PARAGRAPH 84(1)(A) OF THE PATENT RULES Effective date: 20260519 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20260519 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260519 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260520 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260520 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260520 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260520 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260520 Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260520 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260528 |